CNBC November 13, 2024
AstraZeneca said it is doubling down on its investment in its U.S. business, a move that comes just one week after Donald Trump’s election win.
AstraZeneca announced plans for $2 billion in new spending on research and development, bringing its total capital investment in the country to $3.5 billion by the end of 2026. The cash will be used to boost the company’s research and development, as well as its manufacturing footprint in the U.S.
The British-Swedish pharmaceutical giant expects the new investment to create more than 1,000 jobs, “contributing to the growth of the U.S. economy,” according to a release. The company said it currently has 17,800 U.S. employees working across 17 sites in 12 states.
AstraZeneca...
Today's Sponsors
Today's Sponsor